Cargando…

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers

BACKGROUND: Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments. We hypothesized that impaired MBF and myo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Rebecca K., Camaioni, Claudia, Augusto, João B., Knott, Kristopher, Quinn, Ellie, Captur, Gabriella, Seraphim, Andreas, Joy, George, Syrris, Petros, Elliott, Perry M., Mohiddin, Saidi, Kellman, Peter, Xue, Hui, Lopes, Luis R., Moon, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475659/
https://www.ncbi.nlm.nih.gov/pubmed/34310159
http://dx.doi.org/10.1161/JAHA.120.020227
_version_ 1784575449970507776
author Hughes, Rebecca K.
Camaioni, Claudia
Augusto, João B.
Knott, Kristopher
Quinn, Ellie
Captur, Gabriella
Seraphim, Andreas
Joy, George
Syrris, Petros
Elliott, Perry M.
Mohiddin, Saidi
Kellman, Peter
Xue, Hui
Lopes, Luis R.
Moon, James C.
author_facet Hughes, Rebecca K.
Camaioni, Claudia
Augusto, João B.
Knott, Kristopher
Quinn, Ellie
Captur, Gabriella
Seraphim, Andreas
Joy, George
Syrris, Petros
Elliott, Perry M.
Mohiddin, Saidi
Kellman, Peter
Xue, Hui
Lopes, Luis R.
Moon, James C.
author_sort Hughes, Rebecca K.
collection PubMed
description BACKGROUND: Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments. We hypothesized that impaired MBF and myocardial perfusion reserve, quantified using perfusion mapping cardiac magnetic resonance, might occur in the absence of overt left ventricular hypertrophy (LVH) and late gadolinium enhancement, in mutation carriers without LVH criteria for HCM (genotype‐positive, left ventricular hypertrophy‐negative). METHODS AND RESULTS: A single center, case‐control study investigated MBF and myocardial perfusion reserve (the ratio of MBF at stress:rest), along with other pre‐phenotypic features of HCM. Individuals with genotype‐positive, left ventricular hypertrophy‐negative (n=50) with likely pathogenic/pathogenic variants and no evidence of LVH, and matched controls (n=28) underwent cardiac magnetic resonance. Cardiac magnetic resonance identified LVH‐fulfilling criteria for HCM in 5 patients who were excluded. Individuals with genotype‐positive, left ventricular hypertrophy‐negative had longer indexed anterior mitral valve leaflet length (12.52±2.1 versus 11.55±1.6 mm/m(2), P=0.03), lower left ventricular end‐systolic volume (21.0±6.9 versus 26.7±6.2 mm/m(2), P≤0.005) and higher left ventricular ejection fraction (71.9±5.5 versus 65.8±4.4%, P≤0.005). Maximum wall thickness was not significantly different (9.03±1.95 versus 8.37±1.2 mm, P=0.075), and no subject had significant late gadolinium enhancement (minor right ventricle‒insertion point late gadolinium enhancement only). Perfusion mapping demonstrated visual perfusion defects in 9 (20%) carriers versus 0 controls (P=0.011). These were almost all septal or near right ventricle insertion points. Globally, myocardial perfusion reserve was lower in carriers (2.77±0.83 versus 3.24±0.63, P=0.009), with a subendocardial:subepicardial myocardial perfusion reserve gradient (2.55±0.75 versus 3.2±0.65, P=<0.005; 3.01±0.96 versus 3.47±0.75, P=0.026) but equivalent MBF (2.75±0.82 versus 2.65±0.69 mL/g per min, P=0.826). CONCLUSIONS: Regional and global impaired myocardial perfusion can occur in HCM mutation carriers, in the absence of significant hypertrophy or scarring.
format Online
Article
Text
id pubmed-8475659
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84756592021-10-01 Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers Hughes, Rebecca K. Camaioni, Claudia Augusto, João B. Knott, Kristopher Quinn, Ellie Captur, Gabriella Seraphim, Andreas Joy, George Syrris, Petros Elliott, Perry M. Mohiddin, Saidi Kellman, Peter Xue, Hui Lopes, Luis R. Moon, James C. J Am Heart Assoc Original Research BACKGROUND: Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments. We hypothesized that impaired MBF and myocardial perfusion reserve, quantified using perfusion mapping cardiac magnetic resonance, might occur in the absence of overt left ventricular hypertrophy (LVH) and late gadolinium enhancement, in mutation carriers without LVH criteria for HCM (genotype‐positive, left ventricular hypertrophy‐negative). METHODS AND RESULTS: A single center, case‐control study investigated MBF and myocardial perfusion reserve (the ratio of MBF at stress:rest), along with other pre‐phenotypic features of HCM. Individuals with genotype‐positive, left ventricular hypertrophy‐negative (n=50) with likely pathogenic/pathogenic variants and no evidence of LVH, and matched controls (n=28) underwent cardiac magnetic resonance. Cardiac magnetic resonance identified LVH‐fulfilling criteria for HCM in 5 patients who were excluded. Individuals with genotype‐positive, left ventricular hypertrophy‐negative had longer indexed anterior mitral valve leaflet length (12.52±2.1 versus 11.55±1.6 mm/m(2), P=0.03), lower left ventricular end‐systolic volume (21.0±6.9 versus 26.7±6.2 mm/m(2), P≤0.005) and higher left ventricular ejection fraction (71.9±5.5 versus 65.8±4.4%, P≤0.005). Maximum wall thickness was not significantly different (9.03±1.95 versus 8.37±1.2 mm, P=0.075), and no subject had significant late gadolinium enhancement (minor right ventricle‒insertion point late gadolinium enhancement only). Perfusion mapping demonstrated visual perfusion defects in 9 (20%) carriers versus 0 controls (P=0.011). These were almost all septal or near right ventricle insertion points. Globally, myocardial perfusion reserve was lower in carriers (2.77±0.83 versus 3.24±0.63, P=0.009), with a subendocardial:subepicardial myocardial perfusion reserve gradient (2.55±0.75 versus 3.2±0.65, P=<0.005; 3.01±0.96 versus 3.47±0.75, P=0.026) but equivalent MBF (2.75±0.82 versus 2.65±0.69 mL/g per min, P=0.826). CONCLUSIONS: Regional and global impaired myocardial perfusion can occur in HCM mutation carriers, in the absence of significant hypertrophy or scarring. John Wiley and Sons Inc. 2021-07-26 /pmc/articles/PMC8475659/ /pubmed/34310159 http://dx.doi.org/10.1161/JAHA.120.020227 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Hughes, Rebecca K.
Camaioni, Claudia
Augusto, João B.
Knott, Kristopher
Quinn, Ellie
Captur, Gabriella
Seraphim, Andreas
Joy, George
Syrris, Petros
Elliott, Perry M.
Mohiddin, Saidi
Kellman, Peter
Xue, Hui
Lopes, Luis R.
Moon, James C.
Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
title Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
title_full Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
title_fullStr Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
title_full_unstemmed Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
title_short Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
title_sort myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475659/
https://www.ncbi.nlm.nih.gov/pubmed/34310159
http://dx.doi.org/10.1161/JAHA.120.020227
work_keys_str_mv AT hughesrebeccak myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT camaioniclaudia myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT augustojoaob myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT knottkristopher myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT quinnellie myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT capturgabriella myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT seraphimandreas myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT joygeorge myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT syrrispetros myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT elliottperrym myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT mohiddinsaidi myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT kellmanpeter myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT xuehui myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT lopesluisr myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers
AT moonjamesc myocardialperfusiondefectsinhypertrophiccardiomyopathymutationcarriers